Previous 10 | Next 10 |
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer PR Newswire SAN DIEGO , Dec. 19, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to hig...
Regen BioPharma Appoints Two New Scientific Advisory Board Members PR Newswire Company is Bolstering its Scientific Board in the Area of Immunotherapy SAN DIEGO , Dec. 7, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) an...
Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic PR Newswire Initial Design and Testing Complete SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has previously discussed initiation...
Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic PR Newswire DuraCAR Drug Addresses Major Need in Solid Tumor Therapies SAN DIEGO , Nov. 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)ha...
Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space PR Newswire Understanding CAR-T Mechanism of Action SAN DIEGO , Oct. 26, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patent...
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy PR Newswire Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach SAN DIEGO , Se...
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy PR Newswire Company Engages Top-Tier Contract Research Organization SAN DIEGO , Sept. 13, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC P...
Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors PR Newswire Company Develops A Two-Step Sequential Approach SAN DIEGO , Aug. 25, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PIN...
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors PR Newswire Company Creates "Younger T Cells" for Fighting Cancer Using its NR2F6 Technology SAN DIEGO , Aug. 11, 2022 /PR...
The shares of nanocap biotech Regen BioPharma ( OTCPK:RGBP ) surged 21% on Wednesday to reach the highest level since May after the company announced the submission of a U.S. patent application related to a mRNA cancer immunotherapeutic vaccine. The provisional patent appl...
News, Short Squeeze, Breakout and More Instantly...
Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments PR Newswire SAN DIEGO , Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing sev...
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program PR Newswire SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic ( http...
Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program PR Newswire Autoimmunity to be Targeted SAN DIEGO , Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) ...